Scarica l'app Stockscreener
8.53
0.70%
-0.06
Xeris Biopharma Holdings Inc Borsa (XERS) Ultime notizie
XERS Maintains Overweight Rating by Barclays -- Price Target Rai - GuruFocus
Xeris Biopharma: A Commercial Stage Pharma That May Be A Slow-Burn Buy Opportunity (XERS) - Seeking Alpha
Xeris (XERS) Financial Results: EPS Does Not Reach the Reported Estimate in the Available Record; Price Move - vinanet.vn
Rice Hall James & Associates LLC Takes Position in Xeris Biopharma Holdings, Inc. $XERS - MarketBeat
Why Xeris Biopharma (XERS) Is Up 6.6% After Tighter 2026 Revenue Guidance And Wider Losses - Sahm
Xeris Biopharma Holdings (XERS) Could Be 23% Undervalued As Guidance Tightens And Pipeline Progress Continues - Sahm
Xeris Biopharma Holdings Inc (XERS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Walleye Capital LLC Invests $4.84 Million in Xeris Biopharma Holdings, Inc. $XERS - MarketBeat
Why Xeris Biopharma Holdings (XERS) Is Up 8.4% After Tightening 2026 Revenue Guidance And Advancing XP-8121 - Yahoo Finance
Xeris Biopharma Holdings (XERS) Posts Record Q2 Revenue, Is It Still A Bargain? - Yahoo Finance
XERS Q2 2026 Earnings: Steep EPS Miss Weighs on SharesFinancial Summary - vinanet.vn
XERS|Xeris Biopharma Holdings Inc|Price:8.500|Chg%:-0.100 - TradingKey
XERS Q2 2026 Earnings: Significant EPS Miss Weighs on SharesRevenue Per Share - Vinanet
Mission Produce And Two Other Stocks Estimated To Be Trading Below Intrinsic Value - simplywall.st
Xeris Biopharma (NASDAQ:XERS) Insider Sells $42,500.00 in Stock - MarketBeat
Xeris Biopharma (XERS) insider Steven Pieper plans Rule 144 sale of 20,000 shares - Stock Titan
HC Wainwright Comments on Xeris Biopharma FY2026 Earnings - MarketBeat
Janus Henderson Group PLC Boosts Stock Holdings in Xeris Biopharma Holdings, Inc. $XERS - MarketBeat
Renaissance Technologies LLC Cuts Stock Position in Xeris Biopharma Holdings, Inc. $XERS - MarketBeat
Xeris Biopharma Holdings Inc (XERS) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
HC Wainwright Expects Weaker Earnings for Xeris Biopharma - MarketBeat
Xeris Biopharma Holdings, Inc. (XERS) options chain – Yahoo Finance - Yahoo Finance Singapore
Sei Investments Co. Has $3.36 Million Stake in Xeris Biopharma Holdings, Inc. $XERS - MarketBeat
Xeris Biopharma (XERS) Stock Jumps On Record Revenue Despite Wider Losses - Sahm
Xeris Biopharma (NASDAQ:XERS) Downgraded to "Buy" Rating by Wall Street Zen - MarketBeat
Xeris Biopharma Q2 Earnings Call Highlights - MarketBeat
Xeris Biopharma Holdings Inc (XERS) Stock News Today - TradingKey
Xeris Biopharma Holdings, Inc. (XERS) Stock Analysis: A Lucrative 53% Upside Potential for Investors - DirectorsTalk Interviews
Xeris Biopharma (NASDAQ:XERS) Issues Earnings Results, Misses Expectations By $0.19 EPS - MarketBeat
Xeris Biopharma Holdings Inc (XERS) (Q2 2026) Earnings Call High - GuruFocus
XERS Looks 53.1% Overvalued on GF Value™ as Insider Selling Pers - GuruFocus
Xeris Biopharma Holdings, Inc. 2026: Revenue $92.1M, EPS ($0.18) — 10-Q Summary - TradingView
Xeris raises outlook despite posting $31.1 million loss - Crain's Chicago Business
Xeris Biopharma (NASDAQ:XERS) Shares Gap Down Following Weak Earnings - MarketBeat
Is Xeris Biopharma Holdings Inc (XERS) Still a Smart Investment? - GuruFocus
Xeris Biopharma Holdings, Inc. Provides Revenue Guidance for the Full Year 2026 - marketscreener.com
Earnings call transcript: Xeris Biopharma posts Q2 2026 revenue beat, EPS miss - Investing.com
Xeris Biopharma Holdings, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Compared to Estimates, Xeris Biopharma (XERS) Q2 Earnings: A Look at Key Metrics - Yahoo Finance
(XERS) Xeris Biopharma Expects Full Year 2026 Revenue Range $385M$390M, vs. FactSet Est of $385.9M - marketscreener.com
Q2 2026 Xeris Biopharma Holdings Inc Earnings Call Transcript - GuruFocus
Xeris Biopharma: Q2 Earnings Snapshot - marketscreener.com
XERS: Q2 2026 revenue grew 34% year-over-year, driven by Recorlev, with improved margins and strong outlook - TradingView
Xeris Biopharma Reports Second Quarter 2026 Financial Results - Business Wire
Xeris Biopharma (XERS) Plunges 11.78% to $7.16: Stock Nears Critical SupportGap Up Stocks - dars.gov.et
Xeris Q2 FY26 net loss widens to $31.1 million; revenue rises 29% to $92.1 million - Bitget
Xeris Biopharma (XERS) Insider Beth Hecht Sells 16,666 Shares - GuruFocus
Xeris Biopharma (NASDAQ:XERS) Insider Kevin Mcculloch Sells 15,000 Shares of Stock - MarketBeat
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Vanguard Capital Management (XERS) discloses 8.64M-share, 5% holding in Xeris - Stock Titan
XERS Q2'26 Earnings: revenue estimate is 90.12M USD - TradingView
Rice Hall James & Associates LLC Acquires Shares of 251,066 Xeris Biopharma Holdings, Inc. $XERS - MarketBeat
Xeris Biopharma Holdings Inc (XERS) Cash Flow - TradingKey
Xeris Biopharma Holdings Inc (XERS) Income Statement - TradingKey
Xeris Biopharma Holdings Inc (XERS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Xeris Biopharma Holdings Inc (XERS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Xeris Biopharma Holdings Inc (XERS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
XERS|Xeris Biopharma Holdings Inc|Price:8.200|Chg%:-0.120 - TradingKey
Xeris Biopharma Holdings Inc (XERS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Xeris Biopharma Holdings, Inc. Revenue Breakdown – NASDAQ:XERS - TradingView
ETFs Investing in Xeris Biopharma Holdings, Inc. Stocks - TradingView
Xeris Biopharma Holdings, Inc. $XERS Shares Sold by Granahan Investment Management LLC - MarketBeat
Xeris Biopharma Holds Above $8 Support Despite Slight DeclineSeasonality Effect - Vinanet
1.66%
0.33%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):